Marker Therapeutics (MRKR) Gains from Investment Securities (2010 - 2026)
Marker Therapeutics (MRKR) reported Gains from Investment Securities of $1.8 million for Q1 2026, up 1159.2% year-over-year from $140000.0 in Q1 2025, and little changed quarter-over-quarter from $1.8 million in Q4 2025.
Marker Therapeutics (MRKR) Gains from Investment Securities (2010 - 2026) Analysis & Trends
Marker Therapeutics (MRKR) has 16 years of Gains from Investment Securities data on file, last reported at $1.8 million in Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at $1.8 million, up 1159.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.8 million (up 1159.2% YoY), and the FY2025 annual result was $1.8 million, up 1314.95% from the prior year.
- Gains from Investment Securities was little changed at $1.8 million in Q1 2026 per MRKR's latest filing, from $1.8 million in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $10.0 million in Q2 2022 and troughed at $1000.0 in Q1 2023.
- A 5-year average of $1.0 million and a median of $254547.0 in 2022 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2022 and 2024: Gains from Investment Securities sank 99.77% in 2022, then soared 7819.6% in 2024.
- A 5-year view of Gains from Investment Securities shows it stood at $886173.0 in 2022, then fell by 16.73% to $737895.0 in 2023, then plunged by 83.12% to $124589.0 in 2024, then soared by 1314.95% to $1.8 million in 2025, then changed by 0.0% to $1.8 million in 2026.
- Business Quant data shows MRKR's Gains from Investment Securities at $1.8 million in Q1 2026, $1.8 million in Q4 2025, and $140000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Marker Therapeutics | 27.62 Mn | 27.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.76 Mn |
| Mar 31, 2026 | 1.76 Mn |
| Dec 31, 2025 | 1.76 Mn |
| Dec 31, 2025 | 1.76 Mn |
| Sep 30, 2025 | 140,000.00 |
| Sep 30, 2025 | 140,000.00 |
| Jun 30, 2025 | 140,000.00 |
| Jun 30, 2025 | 140,000.00 |
| Mar 31, 2025 | 140,000.00 |
| Mar 31, 2025 | 140,000.00 |
| Dec 31, 2024 | 124,589.00 |
| Dec 31, 2024 | 124,589.00 |
| Sep 30, 2024 | 596,333.00 |
| Sep 30, 2024 | 596,333.00 |
| Jun 30, 2024 | 113,429.00 |
| Jun 30, 2024 | 113,429.00 |
| Mar 31, 2024 | 79,196.00 |
| Mar 31, 2024 | 79,196.00 |
| Dec 31, 2023 | 737,895.00 |
| Dec 31, 2023 | 737,895.00 |